| Literature DB >> 24524463 |
Jean-Rémy Sadeyen, Pete Kaiser, Mark P Stevens, Francis Dziva1.
Abstract
Avian pathogenic Escherichia coli (APEC) cause severe respiratory and systemic disease in poultry yet the nature and consequences of host immune responses to infection are poorly understood. Here, we describe a turkey sub-acute respiratory challenge model and cytokine, cell-mediated and humoral responses associated with protection against homologous re-challenge. Intra-airsac inoculation of turkeys with 105 colony-forming units of APEC O78:H9 strain χ7122nalR induced transient and mild clinical signs of colibacillosis followed by clearance of the bacteria from the lungs and visceral organs. Upon re-challenge with 107 χ7122nalR, primed birds were solidly protected against clinical signs and exhibited negligible bacterial loads in visceral organs, whereas age-matched control birds exhibited high lesion scores and bacterial loads in the organs. Levels of mRNA for signature cytokines suggested induction of a Th1 response in the lung, whereas a distinct anti-inflammatory cytokine profile was detected in the liver. Proliferative responses of splenocytes to either Concanavalin A or soluble χ7122nalR antigens were negligible prior to clearance of bacteria, but APEC-specific responses were significantly elevated at later time intervals and at re-challenge relative to control birds. Primary infection also induced significantly elevated χ7122nalR-specific serum IgY and bile IgA responses which were bactericidal against χ7122nalR and an isogenic Δrfb mutant. Bactericidal activity was observed in the presence of immune, but not heat-inactivated immune serum, indicating that the antibodies can fix complement and are not directed solely at the lipopolysaccharide O-antigen. Such data inform the rational design of strategies to control a recalcitrant endemic disease of poultry.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24524463 PMCID: PMC3937024 DOI: 10.1186/1297-9716-45-19
Source DB: PubMed Journal: Vet Res ISSN: 0928-4249 Impact factor: 3.683
Real-time quantitative RT-PCR probes and primers for turkey cytokines and primers for APEC genes used in this study
| | | | | |
| 28S | Probe | (FAM)-AGGACCGCTACGGACCTCCACCA-(TAMRA) | C, T | [ |
| | Forward | GGCGAAGCCAGAGGAAACT | | |
| | Reverse | GACGACCGATTTGCACGTC | | |
| IL-1β | Probe | (FAM)-CCACACTGCAGCTGGAGGAAGCC-(TAMRA) | C, T | [ |
| | Forward | GCTCTACATGTCGTGTGTGATGAG | | |
| | Reverse | TGTCGATGTCCCGCATGA | | |
| CXCLi2 | Probe | (FAM)-TCTTTACCAGCGTCCTACCTTGCGACA-TAMRA | C,T | [ |
| | Forward | GCCCTCCTCCTGGTTTCAG | | |
| | Reverse | TGGCACCGCAGCTCATT | | |
| IFN-γ | Probe | (FAM)-AAAGATATCATGGACCTGGCCAAGCTTCA-(TAMRA) | T | [ |
| | Forward | AACCTTCCTGATGGCGTGAA | | |
| | Reverse | CTTGCGCTGGATTCTCAAGTC | | |
| IL-13 | Probe | (FAM)-TGCCAGCTGAGCACCGACAACG-(TAMRA) | T | [ |
| | Forward | CCTGCACGGCCAGATGA | | |
| | Reverse | GGCAAGAAGTTCCGCAGGTA | | |
| IL-10 | Probe | (FAM)-CCTGAAGATGACAATGAAGCGCTGTCA-(TAMRA) | T | [ |
| | Forward | CGACCTGGGCAACATGCT | | |
| | Reverse | CCTCTCGCAGGTGAAGAAGTG | | |
| TGF-β4 | Probe | (FAM)-ACCCAAAGGTTATATGGCCAACTTCTGCAT-(TAMRA) | C, T | [ |
| | Forward | AGGATCTGCAGTGGAAGTGGAT | | |
| | Reverse | CCCCGGGTTGTGTTGGT | | |
| | | | | |
| Forward | ATCACATAGGATTCTGCCG | - | [ | |
| | Reverse | CAGCGGAGTATAGATGCCA | | |
| Forward | ACAAAAAGTTCTATCGCTTCC | - | [ | |
| | Reverse | CCTGATCCAGATGATGCTC | | |
| Forward | TGGTAGAATGTGCCAGAGCAAG | - | [ | |
| | Reverse | GAGCTGTTTGTAGCGAAGCC | | |
| Forward | ACTATTCTCTGCAGGAAGTC | - | [ | |
| Reverse | CTTCCGATGTTCTGAACGT |
C = chicken, T = turkey.
The relationship between clinical signs, post-mortem lesions, recoveries of APEC strain 7122nal from lung and liver and splenocyte proliferation in response to 7122nal soluble antigen in the first 14 dpi
| | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | |||||||||||||||||||||||||
| Clinical signs1 | |||||||||||||||||||||||||
| Post-mortem lesions2 | |||||||||||||||||||||||||
| Log10CFU APEC | | | | | | | | | | | | | | | | | | | | | | | | | |
| Lung | 8.9 | 7.6 | 7.2 | 7.5 | 7.6 | 6.1 | 5.2 | 4.2 | 5.1 | 6.8 | 5.3 | 4.2 | 6.4 | 5.4 | 5.3 | 5.2 | 4.2 | 7.0 | 5.8 | 5.6 | 0 | 0 | 0 | 0 | 0 |
| Liver | 8.3 | 7.1 | 6.5 | 5.9 | 6.1 | 4.7 | 4.2 | 1.0* | 1.0* | 1.0* | 4.2 | 1.0* | 4.5 | 1.0* | 0 | 3.2 | 3.3 | 1.0* | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Splenocyte proliferation3 | |||||||||||||||||||||||||
1Depression, ruffled feathers, hunched posture.
2Airsacculitis, pericarditis, perihepatitis, fibrin on serosal surfaces; + = presence any of the clinical or pathological signs; - = absence of any observable clinical or pathological signs. None of these clinical signs or post-mortem lesions was seen in the control group of birds given sterile saline.
3Splenocyte proliferation, - = no response; +a = counts between 200–250 cpm; +b = counts ≥ 2000 cpm.
Bacterial recoveries from lung and liver are given as log10CFU. * = denotes a theoretical value of bacteria obtained after enrichment.
Figure 1Recoveries of nalidixic acid-resistant after primary infection. Two-week-old turkey poults were given 105 CFU of APEC O78:H9 strain χ7122nalR via the intra-airsac route. Five birds were randomly selected, humanely killed and lung (open bars) and liver (shaded bars) sampled for enumeration of bacteria at each time-point. The data represent the mean log10CFU/g tissue ± standard error (SE) of the mean.
Figure 2Levels of cytokine mRNA transcripts in the lung as measured by real-time qRT-PCR (Taqman). Results are expressed as corrected ΔCt values ± SE, in the lungs of challenged (grey bars) and age-matched control (black bars) chickens. Five challenged and three control birds were sampled per time-point. * = P ≤ 0.05.
Figure 3Levels of cytokine mRNA transcripts in the liver as measured by real-time qRT-PCR (Taqman). Results expressed as corrected ΔCt values ± SE, in the livers of challenged (grey bars) and age-matched control (black bars) chickens. Five challenged and three control birds were sampled per time-point.* = P ≤ 0.05.
Figure 4Recoveries of nalidixic acid-resistant from internal organs after homologous re-challenge. APEC-primed turkeys (n = 10) and their age-matched controls (n = 10) were challenged with 107 CFU of APEC strain χ7122nalR via the intra-airsac route and sampled after 24 h. The data represent the mean log10CFU/g tissue ± standard error of the mean.* = P ≤ 0.05; ** = P ≤ 0.01; *** = P ≤ 0.001.
Figure 5Splenocyte proliferation of turkeys at time intervals after primary intra-airsac inoculation. Turkey poults were given 105 CFU of APEC strain χ7122nalR and in uninfected controls were given sterile saline via the same route. Re-stimulation assays were also performed after challenge at day 42. Splenocyte suspensions were separately stimulated with Concanavalin A (positive control; A) and strain χ7122nalR soluble antigen (B). Five birds were sampled from each group at each interval.* = P ≤ 0.05; ** = P ≤ 0.01; *** = P ≤ 0.001.
Figure 6Antibody levels in APEC- and mock-infected birds following primary infection and after homologous re-challenge. The levels were measured by ELISA using different antigens; IgY levels against soluble χ7122nalR antigens (A), IgY levels against O78 LPS purified from χ7122nalR(B) and IgA levels measured against soluble χ7122nalR antigens (C). At 0, 7, 14, 21, and 28 days post-primary infection, five birds per group were sampled and ten birds per group were sampled after re-challenge (day 42). The data in panels B and C reflect levels at post-mortem examination on day 42, one day after re-challenge. * = P ≤ 0.05; ** = P ≤ 0.01.
Figure 7Net replication of APEC strains in LB broth, immune and non-immune turkey sera. Viable counts of χ7122nalR(A) and its isogenic Δrfb mutant (B) were obtained over a 3 h incubation in immune, heat-inactivated immune, non-immune, heat-inactivated non-immune and LB broth. Bacterial counts were determined by sampling 20 μL of culture and performing serial 10-fold dilutions before plating on Mac + Nal agar. The data represent the mean log10 CFU ± standard error from three independent assays performed in triplicate.* = P ≤ 0.05.